Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Inspira Technologies OXY B.H.N. Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
INSPIRA TECHNOLOGIES OXY BHN Aktie jetzt für 0€ handeln | |||||
11.06. | Inspira Technologies: Inspira's ART100 in Use at Tier-1 U.S. Hospitals, Generating Strong Clinical Interest and Accelerating Sales Discussions | 6 | GlobeNewswire (USA) | ||
05.06. | Inspira Technologies boosts production of FDA-cleared system | 2 | Investing.com | ||
05.06. | Inspira Technologies: Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority | 2 | GlobeNewswire (USA) | ||
05.06. | Inspira Technologies OXY B.H.N. Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
29.05. | Inspira Technologies ramps up ART100 system commercialization | 4 | Investing.com | ||
29.05. | Inspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System | 308 | GlobeNewswire (Europe) | RA'ANANA, Israel, May 29, 2025 (GLOBE NEWSWIRE) -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies... ► Artikel lesen | |
27.05. | Inspira Technologies OXY B.H.N. Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
27.05. | Inspira Technologies strukturiert Führungsteam um | - | Investing.com Deutsch | ||
27.05. | Inspira Technologies restructures executive team | 2 | Investing.com | ||
27.05. | Inspira Technologies Aligns Executive Team Amid Corporate Structuring Initiatives | 152 | GlobeNewswire (Europe) | RA'ANANA, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneering company in advanced respiratory support and diagnostic... ► Artikel lesen | |
07.05. | Inspira Technologies OXY B.H.N. Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
07.05. | Inspira Technologies: INSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients | 1 | GlobeNewswire (USA) | ||
23.04. | Inspira Technologies OXY B.H.N. Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
15.04. | Inspira Technologies meldet erste Einnahmen aus FDA-zugelassenem Lebenserhaltungssystem | 2 | Investing.com Deutsch | ||
15.04. | Inspira Technologies reports initial revenue from FDA-cleared life support system | 4 | Investing.com | ||
15.04. | Inspira Technologies OXY B.H.N. Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
15.04. | Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems | 195 | GlobeNewswire (Europe) | RA'ANANA, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, April 15, 2025 -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support... ► Artikel lesen | |
07.04. | Inspira Technologies OXY B.H.N. Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
25.03. | Inspira Technologies OXY B.H.N. Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SERNOVA BIOTHERAPEUTICS | 0,109 | +3,81 % | Sernova Biotherapeutics, Inc.: Sernova Appoints Jonathan Rigby as Interim Chair | LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,745 | -2,49 % | Atossa Genetics Year-end 2024 slides: (Z)-endoxifen shows promise, expenses decline | ||
PING AN HEALTHCARE | 0,946 | +1,42 % | PA GOODDOCTOR (01833): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2025 | ||
MOUNTAIN VALLEY MD | 0,014 | -5,41 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
CO-DIAGNOSTICS | 0,242 | +2,54 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
CYTOSORBENTS | 1,028 | -0,19 % | Cytosorbents Corp: CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb-ATR |
PRINCETON, N.J., June 24, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
VERU | 0,565 | +9,51 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update | Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment... ► Artikel lesen | |
VOLITIONRX | 0,750 | -11,00 % | VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., May 15, 2025 /PRNewswire/... ► Artikel lesen | |
EKSO BIONICS | 3,400 | -4,76 % | XFRA 23E0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEKSO BIONICS. NEW... ► Artikel lesen | |
IMUNON | 0,665 | +4,72 % | Imunon, Inc.: IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 | ASCO 2025 overall survival data bolster IMNN-001's potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism... ► Artikel lesen | |
BEYOND AIR | 0,146 | +3,55 % | Beyond Air-Aktionäre genehmigen Reverse-Aktiensplit | ||
AVINGER | 0,340 | -6,08 % | NSE - Avinger Inc - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
NOVACYT | 0,492 | -0,20 % | Novacyt S.A. - Result of AGM | ||
AROVELLA THERAPEUTICS | 0,071 | +22,61 % | AROVELLA THERAPEUTICS LIMITED: Application for quotation of securities - ALA |